CLINICAL DEVELOPMENT

Pipeline

Publications

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using Hu14.18K322A.‍ ‍Furman, W.L., McCarville, B., Shulkin, B.L., Davidoff, A., Krasin, M., Hsu, C.W., Pan, H., Wu, J., Brennan, R., Bishop, M.W. and Helmig, S., 2022.Journal of Clinical Oncology, 40(4), pp.335-344.

A pilot trial of humanized anti-GD2 monoclonal antibody (Hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. Federico, S.M., McCarville, M.B., Shulkin, B.L., Sondel, P.M., Hank, J.A., Hutson, P., Meagher, M., Shafer, A., Ng, C.Y., Leung, W. and Janssen. 2017. Clin Cancer Res 23(21):pp.6441-6449.

Pre-existing Antitherapeutic Antibodies Against the Fc Region of the Hu14.18K322A mAb are Associated with Outcome in Patients with Relapsed Neuroblastoma. ‍ ‍ Goldberg JL, Navid F, Hank JA, Erbe AK, Santana V, Gan J, de Bie F, Javaid AM, Hoefges A, Merdler M, Carmichael L, Kim K, Bishop MW, Meager MM, Gillies SD, Pandey JP, Sondel PM. J Immunother Cancer. 2020 Mar;8(1):e000590.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.‍ ‍Navid, F., Sondel, P.M., Barfield, R., Shulkin, B.L., Kaufman, R.A., Allay, J.A., Gan, J., Hutson, P., Seo, S., Kim, K. and Goldberg, J., 2014. Journal of clinical oncology, 32(14), p.1445.